Program
navepegritide
Also written as “Navepegritide”, “TransCon CNP” and “Dual therapy with navepegritide and lonapegsomatropin”.
Its studies are mostly in Achondroplasia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascendis Pharma | 54 open or running | phase 3since Oct 30, 2026 | Sep 9, 2019 | Sep 2027phase 2 · NCT06732895 |
| Ascendis Pharma Growth Disorders | 21 open or running | phase 3since Oct 25, 2022 | Oct 25, 2022 | Jan 2039phase 3 · NCT05929807 |
| Visen Pharmaceuticals (Shanghai) | 10 open or running | phase 2since Feb 9, 2022 | Feb 9, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2019First study: phase 2 study in AchondroplasiaNew to Ascendis PharmaAscendis Pharma · NCT04085523 · 57 enrolled · United States, Australia, Austria and more
- Feb 9, 2022Visen Pharmaceuticals (Shanghai)'s first study: phase 2 study in AchondroplasiaNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT05246033 · 24 enrolled · China
- Oct 25, 2022Ascendis Pharma Growth Disorders's first study: phase 3 study in AchondroplasiaNew to Ascendis Pharma Growth DisordersAscendis Pharma Growth Disorders · NCT05598320 · 84 enrolled · United States, Australia, Canada and more
- Jun 6, 2023Phase 3 study in AchondroplasiaAscendis Pharma Growth Disorders · NCT05929807 · 140 planned · United States, Australia, Austria and more
- Oct 6, 2023Phase 2 study in AchondroplasiaAscendis Pharma · NCT06079398 · 72 planned · United States, Australia, Austria and more
- Dec 10, 2024Phase 2 study in AchondroplasiaAscendis Pharma · NCT06732895 · 25 enrolled · Canada, Denmark, France and more
- Oct 30, 20262 phase 3 studiesPhase 3 reachedAscendis Pharma · NCT07924059, NCT07917143
Ahead
- Sep 2027Primary completion: phase 2 study in AchondroplasiaAscendis Pharma · NCT06732895
- Dec 2027Primary completion: phase 2 study in AchondroplasiaAscendis Pharma · NCT06079398
- Sep 2028Primary completion: phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059
- Oct 2028Primary completion: phase 3 study in HypochondroplasiaAscendis Pharma · NCT07917143
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07924059Achondroplasia | 3 | Not yet recruiting | Ascendis Pharma | Sep 2028 | 144 |
| NCT07917143Hypochondroplasia | 3 | Not yet recruiting | Ascendis Pharma | Oct 2028 | 81 |
| NCT06732895Achondroplasia · Canada, Denmark, France and more | 2 | Active, not recruiting | Ascendis Pharma | Sep 2027 | 25 |
| NCT06079398Achondroplasia · United States, Australia, Austria and more | 2 | Recruiting | Ascendis Pharma | Dec 2027 | 72 |
| NCT05929807Achondroplasia · United States, Australia, Austria and more | 3 | By invitation | Ascendis Pharma Growth Disorders | Jan 2039 | 140 |
| NCT05598320Achondroplasia · United States, Australia, Canada and more | 3 | Completed | Ascendis Pharma Growth Disorders | Aug 9, 2024 | 84 |
| NCT05246033Achondroplasia · China | 2 | Completed | Visen Pharmaceuticals (Shanghai) | Mar 15, 2023 | 24 |
| NCT04085523Achondroplasia · United States, Australia, Austria and more | 2 | Completed | Ascendis Pharma | Sep 27, 2022 | 57 |
How it is read
Names in the registry
- “Navepegritide”, 3 entries
- “TransCon CNP”, 3 entries
- “Dual therapy with navepegritide and lonapegsomatropin”, 1 entry
- “Navepegritide (TransCon CNP)”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.